Company profile: Vectura
1.1 - Company Overview
Company description
- Provider of inhalation drug delivery services; formulation development for inhalers, nebulisers, and nasal sprays; comprehensive pharmaceutical analysis; in-house manufacturing of drug products and medical devices for development studies and clinical trials; device platforms for DPI, pMDI, and nebuliser technologies; and process development and technical transfer for airways-related diseases.
Products and services
- Device Platforms: Supports novel or generic programs with DPI, pMDI, and nebuliser technologies, architecting device platforms for inhaled therapies across modalities in a platform-based approach
- Inhalation Drug Delivery: Delivers services to bring inhaled medicines for asthma and COPD to market, focusing on developing inhalation drug delivery systems using a systems-level development approach
- Formulation Development Services: Creates formulations for inhalers, nebulisers, and nasal sprays, with expertise in powder and liquid formulations for inhaled products, employing a multi-phase technical framework
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vectura
Continuus Pharmaceuticals
HQ: United States
Website
- Description: Provider of Build-Own-Operate integrated continuous manufacturing solutions for small molecule pharmaceuticals, designing, building, and running client-site processes. Offerings include end-to-end ICM pilot plants, continuous reactive crystallization, solvent recovery systems, EMC for oral solid dosage forms, and automated modular assembly lines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Continuus Pharmaceuticals company profile →
Jubilee Clinical Research
HQ: United States
Website
- Description: Provider of clinical research across diverse indications, including new antibiotic developments and the latest diabetic therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jubilee Clinical Research company profile →
Exploristics
HQ: United Kingdom
Website
- Description: Provider of biosimulation software and biostatistics services for designing, analyzing, and reporting clinical trials and real studies. Offers KerusCloud, a simulation platform for tailored study design; biostatistics and statistical consulting; data science services using advanced analytics, machine learning, and predictive modeling; and an Analytics Academy for training in statistical analysis and programming.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exploristics company profile →
Syrrx
HQ: United States
Website
- Description: Provider of drug discovery services leveraging high-throughput structural biology, focusing on drug targets validated in human clinical trials and directing efforts toward therapeutics for metabolic diseases, cancer, and inflammation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Syrrx company profile →
Senn Chemicals
HQ: Switzerland
Website
- Description: Provider of peptide development and manufacturing services, spanning intermediates to CGMP API and supporting discovery through commercial production. In the peptide business since 1963, SENN offers expertise to optimize processes and streamline scale-up.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Senn Chemicals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vectura
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vectura
2.2 - Growth funds investing in similar companies to Vectura
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vectura
4.2 - Public trading comparable groups for Vectura
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →